Kerry Conlin
YOU?
Author Swipe
View article: Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study Open
The ChAdOx1 nCoV-19 fourth dose is well tolerated and boosts humoral immunity; this was evident as an increased humoral response across multiple variants of concern. These data support its use as a booster dose against SARS-CoV-2 infection.
View article: Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial Open
NCT04536051.
View article: Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology
Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology Open
This study was funded by the Meningitis Research Foundation, Pfizer and the NIHR Programme Grants for Applied Research.
View article: Accelerating clinical development of a live attenuated vaccine against <i>Salmonella</i> Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of <i>Salmonella</i> Paratyphi A infection in healthy adult volunteers
Accelerating clinical development of a live attenuated vaccine against <i>Salmonella</i> Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of <i>Salmonella</i> Paratyphi A infection in healthy adult volunteers Open
Introduction This is the first efficacy study of an oral live attenuated vaccine against Salmonella Paratyphi A using a human challenge model of paratyphoid infection. S . Paratyphi A is responsible for 3.3 million cases of enteric fever e…